A Study of PF-07321332/Ritonavir in Non-hospitalized Low-Risk Adult Participants With COVID-19
Status:
Recruiting
Trial end date:
2022-02-28
Target enrollment:
Participant gender:
Summary
The primary hypothesis to be tested is whether or not there is a difference in time to
sustained alleviation of all targeted COVID-19 signs and symptoms through Day 28 between
PF-07321332/ritonavir and placebo.